0000950170-24-124624 | 10-Q | RAPT Therapeutics, Inc.

Quarterly report which provides a continuing view of a company's financial position. Filing Group. Quarterly Filings. Company. RAPT Therapeutics, Inc. Issuer. RAPT Therapeutics, Inc. Filing …

CouponFollow Extension

$18
OFF

RAPT Therapeutics Inc (RAPT) Quarterly 10-Q Report

1 week from now

5 days ago · RAPT reported a net loss of $18.4 million for the quarter, compared to $31.4 million in the previous year. The decrease in net loss is attributed to reduced operating expenses. …

qz.com

$18
OFF

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

1 week from now

5 days ago · Third Quarter Ended September 30, 2024. Net loss for the third quarter of 2024 was $18.4 million, compared to $31.4 million for the third quarter of 2023. Research and …

rapt.com

$18
OFF

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

1 week from now

5 days ago · Third Quarter Ended September 30, 2024. Net loss for the third quarter of 2024 was $18.4 million, compared to $31.4 million for the third quarter of 2023. Research and …

businessinsider.com

$30
OFF

RAPT Therapeutics Reports First Quarter 2024 Financial Results

1 week from now

May 9, 2024 · Financial Results for the First Quarter March 31, 2024. First Quarter Ended March 31, 2024. Net loss for the first quarter of 2024 was $30.5 million, compared to $29.3 million for …

rapt.com

$31
OFF

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

1 week from now

Third Quarter Ended September 30, 2023. Net loss for the third quarter of 2023 was $31.4 million, compared to $21.2 million for the third quarter of 2022. Research and development expenses …

rapt.com

$0.71
OFF

RAPT Therapeutics (RAPT) Earnings Date And Reports 2024

1 week from now

RAPT Therapeutics released Q2 2024 earnings on August 8, 2024, reporting an EPS of -$0.71, which topped the consensus estimate of -$0.74 by $0.03. With a trailing EPS of -$2.77, RAPT …

marketbeat.com

FAQs about 0000950170-24-124624 | 10-Q | RAPT Therapeutics, Inc. Coupon?

How many research reports have been made about rapt Therapeutics?

In the past 90 days, only 4 research reports have been made about RAPT Therapeutics. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company that engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. ...

What is RAPT Therapeutics?

RAPT Therapeutics, Inc. is a clinical stage immunology-based biopharmaceutical company that discovers, develops, and commercializes oral small molecule therapies for patients in oncology and inflammatory diseases. It was founded in 2015 and is headquartered in South San Francisco, CA. ...

What are the 12 month price targets for rapt Therapeutics (rapt)?

According to 8 Wall Street analysts, the 12 month price range for RAPT Therapeutics' shares is between $23.00 and $48.00. The average prediction is that the company's stock price will reach $41.44 in the next twelve months, indicating a possible upside of 109.7% from the current price. ...

Is RAPT Therapeutics (RAPT) a good stock to buy?

According to analysts, RAPT Therapeutics has a consensus rating of Buy. The company's average rating score is 3.00, based on 8 buy ratings, no hold ratings, and no sell ratings. The consensus price target of $41.44 implies a forecasted upside of 109.7% from its current price of $19.76. ...

What is the upside for rapt Therapeutics (rapt)?

According to analysts' consensus, RAPT Therapeutics has a forecasted upside of 109.7%, with a price target of $41.44, which is higher than its current price of $19.76. RAPT Therapeutics has only been the subject of 4 research reports in the past 90 days. ...